Tag: 0001

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

Water Instead of Diet Drinks Associated with Two-Fold Rate of Diabetes Remission in Women

New Research Demonstrates Significant Benefits of Simple Dietary Switch for Blood Glucose Control and Long-Term Weight Management CHICAGO, June 20, 2025 /PRNewswire/ -- Consistently replacing...

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and...

DEMIRE Anleihe 2019/2027: Erstrating B von Fitch

Fitch Ratings hat der DEMIRE erstmals ein Emittentenrating von „CCC+“ erteilt. Die Anleihe (ISIN: DE000A2YPAK1) wurde mit "B" eingestuft.

DEMIRE bond 2019/2027: Initial rating B from Fitch

Fitch Ratings has assigned DEMIRE an issuer rating of ‘CCC+’ for the first time. Fitch Ratings has assigned the bond (ISIN: DE000A2YPAK1) a ‘B’ rating.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTags0001

FemiCore [Exclusive Report 2026] Femi Core Warning Why Thousands of Women Are Suddenly Talking About This Bladder Health Supplement

There Are 16 Minerals America Produces None Of. The Government Now Calls That a National Security Threat.

Glacier Breeze Portable AC: Features, Performance Claims & Consumer Feedback Evaluated in 2026

Tag: 0001

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

Water Instead of Diet Drinks Associated with Two-Fold Rate of Diabetes Remission in Women

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

DEMIRE Anleihe 2019/2027: Erstrating B von Fitch

DEMIRE bond 2019/2027: Initial rating B from Fitch

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us